Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 13

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 13
---
 shareholders and our board of directors, liquidate and dissolve,
subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable
law. There will be no redemption rights or liquidating distributions with respect to our rights, which will expire worthless if we fail
to complete our initial business combination within the prescribed time period. Our public shareholders will be permitted to redeem their
shares regardless of whether they abstain, vote for, vote against, or vote at all with respect to the proposed business combination.

Our sponsor has entered into
written agreements with us, pursuant to which it has waived its rights to liquidating distributions from the trust account with respect
to any founder shares it holds if we fail to complete our initial business combination within the completion window. However, if our sponsor
acquires public shares, it will be entitled to liquidating distributions from the trust account with respect to such public shares if
we fail to complete our initial business combination within the completion window.

7

Our sponsor, directors, and
officers have agreed, pursuant to written agreements with us, that they will not propose any amendment to our amended and restated memorandum
and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion
window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination
activity, unless we provide our public shareholders with the opportunity to redeem their ordinary shares upon approval of any such amendment
at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (net of
funds withdrawn to pay our taxes, if any, and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued
and outstanding public shares.

If we were to expend all of the net proceeds of the IPO and the sale of
the Private Placement Units, other than the proceeds deposited in the trust account, and without taking into account interest, if any,
earned on the trust account, the per-share redemption amount received by shareholders upon our dissolution would be approximately $10.05.
The proceeds deposited in the trust account could, however, become subject to the claims of our creditors which would have higher priority
than the claims of our public shareholders. Under Cayman laws,